ClinicalTrials.gg
RecruitingNCT06094660RADIOPHENOLUpdated Dec 5, 2023

RFA or Chemical Neurolysis of the Genicular Nerves Compared to Conservative Treatment for Knee Pain Caused by OA

An interventional study of Diagnostic genicular nerve block and Genicular nerve block with Radiofrequency Ablation (RFA) in Osteo Arthritis Knee and Knee Pain Chronic, sponsored by Dijklander Ziekenhuis. Recruiting at 2 sites in Netherlands. Open to participants aged 35 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-12-05.

Sponsored by Dijklander Ziekenhuis · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
35 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Pain with a site in Netherlands — 10 open to participants now, 13 under way, 1 of them phase 3. Pain · Netherlands.

Planned enrollment
20th of 86
192 · median 85
Started
2023
with 7 others
No phase
43 of 106
7 open now
Primary completion
2026-11
later than 8 of 12 live
Registered
96th of 106
by date

Among the 106 studies in Pain with a site in Netherlands, this one is the 20th largest by planned enrollment of the 86 interventional ones that give a count, is one of 8 that started in 2023, is one of 43 with no phase, reaches primary completion later than 8 of the 12 other live ones, and was the 96th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

10 of the 106 studies in Pain with a site in Netherlands are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 35 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Pain with a site in Netherlands, or all of them as a file.
02

Study summary

A randomised controlled triall (RCT) with three parallel arms comparing the functional outcome of chemical ablation with phenol and radiofrequency ablation (RFA) of the genicular nerves with conservative treatment in patients with chronic knee pain caused by osteoarthritis (OA).

Read the detailed description

In guidelines for knee osteoarthritis (OA), conservative treatments are physical therapy, analgesics and intra-articular injections with corticosteroids. In severe OA and persisting symptomatic cases the golden standard is joint replacing surgery. A less invasive technique is ablation of the sensory (genicular) nerves of the knee. This technique is beneficial for younger patients as a bridge to surgery or patients that cannot undergo total knee arthroplasty (TKA) due to comorbid health conditions. Nerve ablation can either be done with chemical agents or thermal energy.

Although there are numerous studies on genicular nerve block for chronic knee pain caused by OA, there are just a few small studies that compare genicular nerve block with conservative treatment.To be able to determine if genicular nerve ablation is efficacious to serve the gap between conservative treatment and TKA, this randomised controlled trial (RCT) compares two forms of genicular nerve ablation (radiofrequency and phenolisation; intervention) with conservative treatment (control) up to 6 months after treatment.

03

Conditions studied

  • Osteo Arthritis Knee
  • Knee Pain Chronic

Browse trials for

Keywords

  • Pain
  • Thermal ablation
  • Phenol neurolysis
  • Genicular nerve
04

Who can participate

Ages eligible
35 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients of both sexes, >35 years who are not a candidate for TKA due to young age, old age, comorbidity or technical reasons.
  2. OKS \< 30 on a scale from 0 (severe function) to 48 points (satisfactory function).
  3. Continued pain in the target knee that is moderate to severe (defined as NRS ≥ 6 on an 11-point NRS scale) either constantly or with motion despite at least 3 months of conservative treatments. Conservative treatment can include: active physiotherapy, pharmacological treatment of pain (acetaminophen or NSAIDs) and intra-articular infiltration.
  4. Radiologic confirmation of arthritis for the target knee. Defined as the Kellgren Lawrence (KL) score of 2 or more on X-ray or MRI.

Exclusion criteria

Exclusion Criteria:

  1. Patient with prior ablation of the genicular nerves, prior partial, resurfacing, or TKA of the target knee (residual hardware).
  2. Patient with a history of neurovascular injury or recent trauma of the lower extremities.
  3. Patient with chronic widespread pain.
  4. Polyneuropathy and/or radicular pain in the lower extremities.
  5. Patient is currently implanted with a neurostimulator.
  6. Local or systemic infection (bacteraemia).
  7. Uncontrolled immune suppression.
  8. Intra-articular injections (, hyaluronic acid, enriched plasma, stem cell, ...) in the target knee within 90 days from randomisation.
  9. Arthroscopic debridement/lavage into the target knee within 180 days from randomisation.
  10. \<18,5 kg/m2 and patients with minimal subcutaneous tissue thickness that would not accommodate ablation with phenol or radio frequency (risk of skin burns).
  11. Allergies to products used during the procedure (lidocaine, phenol, contrast dye).
  12. Patients who have a planned TKA in the near future, defined as patients who already have agreed on a date for the TKA procedure.
  13. Patients with psychosocial problems as determined by the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
192 participants (estimated)

Study arms

  • Active comparator
    Chemical ablation of the genicular nerves with Phenol 6%

    Chemical ablation with phenol is done by injection of 1,5ml of phenol 6 % at the superomedial, the superolateral and the inferomedial genicular nerve.

    Procedure: Diagnostic genicular nerve block · Procedure: Genicular nerve block with Phenol 6%

  • Active comparator
    Radiofrequency ablation (RFA) of the genicular nerves

    In our study we will make two RFA lesions at every target with 80°C for 90 seconds with a 5mm active tip. So we will make 6 lesions in total. The targets are the superomedial, the superolateral and the inferomedial genicular nerve.

    Procedure: Diagnostic genicular nerve block · Procedure: Genicular nerve block with Radiofrequency Ablation (RFA)

  • No intervention
    Conservative treatment

    Examples of allowed conservative treatments during the study are patient education, physical therapy, weight loss and different pharmacological treatments.

Interventions

  • ProcedureDiagnostic genicular nerve block

    Diagnostic block will be done with 1,5ml of Lidocaine 2% at the 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve.

  • ProcedureGenicular nerve block with Radiofrequency Ablation (RFA)

    Genicular nerve block with RFA will be performed at 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve. Radiofrequency ablation (RFA) is performed by creating two RFA lesions at the 3 treatment sites (6 lesions in total) after local anesthesia with 1,5ml lidocaine 2%. The lesions are made by heating the 5mm active tip of the needle to 80°C for 90 seconds.

  • ProcedureGenicular nerve block with Phenol 6%

    Genicular nerve block with Phenol 6% will be performed at 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve. Chemical ablation with phenol is done by injection of 1 ,5ml of phenol 6 % at the 3 target sites after infiltration with contrast dye to rule out intravascular injection. Because infiltration with phenol is painless, prior infiltration of the target site with al local anaesthetic is not necessary.

06

What researchers measure

Primary outcomes

  1. Knee function measured with the Oxford Knee score (OKS)

    Questionnaire with 12 items. Scores can range from 0 to 48, with 48 being the best outcome and a lower score indicates more functional limitations and pain.

    Time frame: During intake, before the intervention or study start in conservative group (T=0) and during the follow up visits (T=1 at 6weeks, T=2 at 3 months, T=3 at 6 months and T=4 at 12 months after the intervention or study start).

Secondary outcomes

  1. Osteoartritis (OA) measured by the Western Ontario and McMaster Universities Arthritis Index (WOMAC)

    We will use the WOMAC in the Likert version where question are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4). The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. So the sum of the scores ranges from 0 (the best) to 96 (the worse).

    Time frame: Before the intervention or study start in conservative group (T=0) and during the follow up visits (T=1 at 6weeks, T=2 at 3 months, T=3 at 6 months and T=4 at 12 months after the intervention or study start).

  2. Pain measured with the Numeric Rating Score (NRS)

    NRS will be measured in rest and during the performance based tests.

    Time frame: In rest during intake and in rest and during performance based tests before and after the diagnostic nerve block (if applicable), before the intervention (if applicable), 6 weeks, 3 months, 6 months and 1 year after the intervention

  3. 30 seconds chair-stand test

    During this test the total number of complete chair stands (up and down represents one stand) is counted. If at least a full stand is completed at 30 seconds this is counted in the total. If a person cannot stand even once then the score for the test is zero.

    Time frame: Before and after the diagnostic block, before the intervention (T=0), and at 6 weeks, 3 months, 6 months and 12 months follow up. In the conservative treatment group this will only be done at the applicable follow up dates.

  4. 40 meters (4x10m) fast-paced walk test

    The total time taken to walk the 4 × 10 m, excluding turns, of one trial is recorded and expressed as speed m/s by dividing distance (40 m) by time (seconds). Timing is paused during turns.

    Time frame: Before and after the diagnostic block, before the intervention (T=0), and at 6 weeks, 3 months, 6 months and 12 months follow up. In the conservative treatment group this will only be done at the applicable follow up dates.

  5. 9-steps stair-climb test

    Total time to ascend and descend steps for one trial is recorded in seconds.

    Time frame: Before and after the diagnostic block, before the intervention (T=0), and at 6 weeks, 3 months, 6 months and 12 months follow up. In the conservative treatment group this will only be done at the applicable follow up dates.

  6. Health related quality of life with the EQ-5D-5L

    The EQ-5D descriptive system comprises the following five dimensions, each describing a different aspect of health: MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN / DISCOMFORT and ANXIETY / DEPRESSION. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The respondent is asked to indicate his / her health state by checking the box against the most appropriate statement in each of the five dimensions. EQ-5D comprises a short questionnaire that is cognitively undemanding, taking only a few minutes to complete.

    Time frame: Before the intervention or study start in conservative group (T=0) and during the follow up visits (T=1 at 6weeks, T=2 at 3 months, T=3 at 6 months and T=4 at 12 months after the intervention or study start).

  7. Hospital Anxiety and Depression Scale (HADS)

    The Dutch version of the HADS is a fourteen-item scale with seven items for anxiety (HADS-A) and seven items for depression (HADS-D) (49). Scoring for each item ranges from zero to three. A higher score indicates more anxiety or depression.

    Time frame: At T=0 (before intervention) and during T=3 (6 months after intervention)

  8. Pain Catastrophizing Score (PCS)

    The Pain Catastrophizing Scale (PCS) is a 13-item self-report questionnaire considered to be the most frequent and extensively studied tool to assess pain catastrophizing for chronic pain. Patients are asked to rate the degree to which they have any of the thoughts described in the questionnaire using a 5-point Likert scale ranging from 0 (never) to 4 (always). The total score is the sum of the scores for the individual items, and ranges from 0 to 52. Higher scores indicate a higher level of catastrophizing.

    Time frame: At T=0 (before intervention) and during T=3 (6 months after intervention)

  9. Diagnostic block most appropriate cut-off value

    The continuous results of the diagnostic nerve block in our study (percentage of pain relief) will be used to determine the best cut-off value for the positive outcome of the ablation. The cut-off value will be analysed with a receiver operating curve (ROC) analysis. Results equal or above this cut-off value are considered to predict a positive outcome of the ablation of the nerves, results below the cut-off value are considered to predict a negative outcome of the ablation of the nerve. For this analysis, a positive outcome of the ablation is defined as a MCID in OKS of 4.9 points at 3 months follow up.

    Time frame: Before and after the diagnostic block and during T=2 (3 months after intervention).

  10. Patient satisfaction

    The patient satisfaction with the result of treatment will be measured with a 5-point Likert scale (1-5). The patients will be asked to grade the statement 'I am satisfied with the result of the treatment' with the following options: 1. Strongly disagree 2. Disagree 3. Neutral 4. Agree 5. Strongly agree

    Time frame: During the follow up visits (T=1 at 6weeks, T=2 at 3 months, T=3 at 6 months and T=4 at 12 months after the intervention or study start).

  11. Patient Global Impression of Change (PGIC)

    The PGIC in pain and function will be measured with a 5-point Likert scale (1-5) on the applicable follow up visits. The patients will be asked to rate the following statements: * Please imagine how you would have described your pain intensity before the procedure. How do you feel today as compared to baseline (Start of the study) as far as your knee pain caused by OA is concerned? * Please imagine how you would have described the functionality of your knee before the procedure. How do you feel today as compared to baseline (start of the study) as far as your knee functionality caused by OA is concerned? The options on the Likert scale are: 1. much better 2. slightly better 3. no change 4. slightly worse 5. much worse

    Time frame: During the follow up visits (T=1 at 6weeks, T=2 at 3 months, T=3 at 6 months and T=4 at 12 months after the intervention or study start).

  12. Minimal Clinically Important Difference (MCID) of the OKS

    We will use distribution and anchor based methods to determine the MCID on the patient reported outcomes of the OKS.

    Time frame: MCIDs will be determined for our population on T=1 (6weeks), T=2 (3 months) and T=3 (6 months) follow up. .

  13. Minimal Clinically Important Difference (MCID) of the WOMAC

    We will use distribution and anchor based methods to determine the MCID on the patient reported outcomes of the WOMAC.

    Time frame: MCIDs will be determined for our population on T=1 (6weeks), T=2 (3 months) and T=3 (6 months) follow up.

  14. Minimal Clinically Important Difference (MCID) for the EQ-5D-5L

    To determine the MCID on the patient reported outcomes of the EQ-5D-5L we will use an instrument defined method.

    Time frame: MCIDs will be determined for our population on T=1 (6weeks), T=2 (3 months) and T=3 (6 months) follow up.

  15. Minimal Clinically Important Difference (MCID) of the 30 seconds chair-stand test

    We will use distribution and anchor based methods to determine the MCID of the 30 seconds chair-stand test.

    Time frame: MCIDs will be determined for our population on T=1 (6weeks), T=2 (3 months) and T=3 (6 months) follow up.

  16. Minimal Clinically Important Difference (MCID) of the 40 meters (4x10m) fast-paced walk test

    We will use distribution and anchor based methods to determine the MCID of the 40 meters (4x10m) fast-paced walk test.

    Time frame: MCIDs will be determined for our population on T=1 (6weeks), T=2 (3 months) and T=3 (6 months) follow up.

  17. Minimal Clinically Important Difference (MCID) of the 9-steps stair-climb test.

    We will use distribution and anchor based methods to determine the MCID of the 9-steps stair-climb test.

    Time frame: MCIDs will be determined for our population on T=1 (6weeks), T=2 (3 months) and T=3 (6 months) follow up.

  18. Adverse events

    The reported treatment related or probably treatment related adverse events will be listed as numbers with frequencies per treatment.

    Time frame: After the diagnostic block, after the intervention (T=0), and at 6 weeks, 3 months, 6 months and 12 months follow up.

  19. Medication changes

    The patients will be asked to report changes in the use of NSAIDs and opioids during the follow up visits. The results will be summarised as increased use, no change, decrease in use and use of opioids will be reported as MME.

    Time frame: Before the intervention (T=0), and at 6 weeks, 3 months, 6 months and 12 months follow up.

  20. Number of Total Knee Artroplasty's (TKA's)

    The number of TKAs during the study follow up will be documented including the point in time since the intervention. If applicable, we will use the Kaplan-Meier estimator to estimate the survival function.

    Time frame: At 6 weeks, 3 months, 6 months and 12 months follow up.

  21. Procedure time

    The total procedure time of chemical ablation and RFA will be measured in minutes. The measurement starts as soon as the treating physician puts on his sterile gloves and will end when the sterile draping is taken off.

    Time frame: During the intervention visit (T=0)

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The study protocol and the final data will be published. Conditions for reuse apply: A de-identified dataset will be made available upon request to the corresponding author. The request must include ethics approval and a statistical analysis plan. An embargo period applies: The embargo period is at least 1 year after the publication of the original study.

Time frame: An embargo period applies: The embargo period is at least 1 year after the publication of the original study.

Access criteria: A de-identified dataset will be made available upon request to the corresponding author. The request must include ethics approval and a statistical analysis plan. Digital data and documentation will be preserved for 15 years.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Nov 2026, 35 months after the start.

Of 3,740 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 35 months is above that.

Counting every sponsor, half of 3,839 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2023
First posted
Oct 23, 2023
StartActual
Nov 27, 2023
Primary completionEst.
Nov 1, 2026
CompletionEst.
Nov 1, 2026
Last update
Dec 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06094660
Lead sponsor
Dijklander Ziekenhuis
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Nov 27, 2023
Primary completion
Nov 1, 2026 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
Dec 5, 2023

Study contacts

Gezina Oei, MD,PhD
Contact
g.t.m.l.oei@dijklander.nl
0031229257257
Aine Honohan, MSc
Contact
a.g.honohan@Dijklander.nl
0031646340596
Gezina Oei, MD, PhD
principal investigator · Academic Medical Centre Amsterdam
Markus Hollmann, Prof
study chair · Academic Medical Centre Amsterdam

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion